KOBV Portal

Hits per page

hit 1 - 1 | 1 hit

Select All Export

Online Resource

Successful use of palifermin following severe anaphylaxis to pegaspargase in a pediatric patient with acute lymphoblastic leukemia

Kaminski, Katie S ; Beach, Cassidy L ; Peden, David B ; [et al.]

SAGE Publications ; 2016

In: Journal of Oncology Pharmacy Practice Vol. 22, No. 2 ( 2016-04), p. 354-356

add to watchlist on the watchlist

Details

In: Journal of Oncology Pharmacy Practice, SAGE Publications, Vol. 22, No. 2 ( 2016-04), p. 354-356

Abstract: Palifermin and pegaspargase are Escherichia coli-derived drug products. Hypersensitivity reactions, including anaphylaxis, are frequently reported with pegaspargase. In high-risk acute lymphoblasic leukemia (ALL), patients undergoing allogeneic hematopoietic stem cell transplant may be treated with palifermin as a supportive care measure for mucositis prophylaxis. However, no literature exists documenting the cross-reactivity between palifermin and pegaspargase. We report a case in which a child with very high-risk ALL having experienced severe anaphylaxis with pegaspargase was later successfully treated with palifermin during stem cell transplant conditioning.

Type of Medium: Online Resource

ISSN: 1078-1552 , 1477-092X

URL: Article

DOI: 10.1177/1078155214567165

Language: English

Publisher: SAGE Publications

Publication Date: 2016

detail.hit.zdb_id: 2026590-6

SSG: 15,3